Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Incyte reports 71% response rate for INCA33890 combination in Phase 1 colorectal cancer trial

By Public Technologies
  • Incyte presented early-stage results for cancer treatments INCB161734 and INCA33890 at the ESMO Congress 2026.
  • INCB161734 combinations showed durable responses in pancreatic cancer and antitumor activity in previously treated colorectal cancer, with manageable safety.
  • INCA33890 with standard therapies showed preliminary activity across microsatellite-stable colorectal cancer patient groups, with manageable safety.
  • Phase 3 pancreatic cancer results for INCB161734 are expected in 2028; its colorectal cancer trial should begin in the first half of 2027.
  • The ongoing Phase 3 trial of INCA33890 with chemotherapy and bevacizumab in first-line microsatellite-stable colorectal cancer expects results in 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026987057) on October 26, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.